SCHEMBL31068637

SCHEMBL31068637

Cn1cnc2cnc(OCc3ccccc3)nc21

nearest known ligand 0.66

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 20/20 0.66
ALDH1A1 P00352 15/20 0.66
TSHR P16473 11/20 0.66
CLK4 Q9HAZ1 1/20 0.66
CYP2C19 P33261 11/20 0.58
CYP2C9 P11712 8/20 0.58
CYP2D6 P10635 3/20 0.58
CYP3A4 P08684 12/20 0.58
HSD17B10 Q99714 7/20 0.57
CASP1 P29466 5/20 0.57
CASP7 P55210 5/20 0.57
LMNA P02545 4/20 0.56
MAPK1 P28482 4/20 0.56
HIF1A Q16665 3/20 0.55
USP2 O75604 4/20 0.52
MEN1 O00255 1/20 0.52
KMT2A Q03164 1/20 0.52
HPGD P15428 3/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31068655 0.78 PDE10A (0.48) CYP1A2ALDH1A1TSHRCLK4
SCHEMBL8674551 0.74 CDK1 (0.59) CYP1A2ALDH1A1TSHRCLK4CYP2C19
SCHEMBL24394711 0.73 CYP1A2 (0.44) CYP1A2ALDH1A1TSHRCLK4CYP2C19
SCHEMBL30545109 0.73 CYP1A2 (0.44) CYP1A2ALDH1A1TSHRCLK4CYP2C19
SCHEMBL31068640 0.71 GABRP (0.44) CYP1A2ALDH1A1TSHRCLK4CYP2C19
SCHEMBL10615795 0.70 STAT3 (0.51) CYP1A2ALDH1A1TSHRCLK4CYP2C19
SCHEMBL26971403 0.69 CYP1A2 (0.57) CYP1A2ALDH1A1TSHRCLK4CYP2C19
SCHEMBL11009131 0.68 TSHR (0.52) CYP1A2TSHRCYP2C19CYP3A4LMNA
SCHEMBL5440110 0.68 CYP1A2 (0.48) CYP1A2ALDH1A1TSHRCLK4CYP2C19
SCHEMBL21514306 0.68 CYP1A2 (0.52) CYP1A2ALDH1A1TSHRCLK4CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240254114-A1 PREPARATION OF FUSED AZOLE DERIVATIVES AS NOVEL DIACYLGLYCERIDE 0-ACYLTRANSFERASE 2 INHIBITORS MERCK SHARP & DOHME LLC (US) 2024-08-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240254114-A1 PREPARATION OF FUSED AZOLE DERIVATIVES AS NOVEL DIACYLGLYCERIDE 0-ACYLTRANSFERASE 2 INHIBITORS DGAT2, DGAT1, ACAT2 CYP1A2 126/4885ALDH1A1 984/4885TSHR 4284/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.